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See Article by Lupón et al T he longitudinal trajectory of left ventricular (LV) ejection fraction (EF) in heart failure (HF) with preserved EF (HFpEF) is important for categorizing HF into distinct HFpEF (LVEF >50%), HF with midrange EF (HFmrEF; 40% <LVEF <50%), and HF with reduced EF (HFrEF <40%) phenotypes. A significant decline of LVEF over time suggests HFpEF to be a mere precursor stage of HFmrEF or HFrEF, whereas constancy of LVEF supports HFpEF to be a distinct HF phenotype driven by unique pathophysiological mechanisms. In this issue of Circulation: Heart Failure, Lupón et al 1 provide compelling evidence for the latter as they convincingly demonstrate in a prospective study with 11 years of follow-up that there was only a minimal decline in LVEF (±0.5% annually) and that only 9.5 and 1.6% of HFpEF patients transitioned respectively to the HFmrEF and HFrEF phenotypes. As expected, transition was more common in the presence of coronary artery disease (CAD). Furthermore, in contrast to a similar report by the same investigators in HFrEF, there was no relation between a decline in LVEF and subsequent mortality.
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HISTORICAL PERSPECTIVE
Interest into the longitudinal trajectory of LV systolic function in HFpEF was triggered by echocardiographic studies performed in 2007 and showing reduced tissue Doppler mitral annular long-axis shortening (s′) in cross-sectional cohorts of HFpEF patients. This subtle reduction in LV systolic function was not evident on LVEF measurements. Investigators, therefore, speculated the low s′ to be an initial sign of a systolic function deficit which over time would evolve to a manifest reduction in LVEF. 3 This hypothesis suggested HF to be a mechanistic continuum with HFpEF a mere precursor of HFrEF and led eminent HF scholars to qualify HFpEF as a myth or a nonexisting disease. 4 Supporters of the HF continuum hypothesis defended their viewpoint by referring to rodent HF models in which transverse aortic constriction resulted initially in concentric LV remodeling resembling HFpEF and later in eccentric LV remodeling resembling HFrEF. The presumed analogy with the rodent transverse aortic constriction models also implied LV remodeling in HFpEF to be driven by myocardial overload imposed by arterial hypertension or arterial stiffness and not as recently proposed, by metabolic comorbidities, systemic inflammation, and microvascular dysfunction. 5 The validity of the HF continuum hypothesis rested heavily on the longitudinal trajectory of LVEF in HFpEF patients, which was supposed to decline as years passed by. Consequently, the LVEF trajectory was assessed in several studies, most of which were however hampered by a lack of prospective design and a short follow-up period. [6] [7] [8] In this issue of Circulation: Heart Failure, the study of Lupón et al 1 overcame both obstacles as it prospectively
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Phenotypic Persistence in Heart Failure With Preserved Ejection Fraction recruited a cohort of HFpEF patients for scheduled repeat echocardiograms at predetermined intervals over an 11-year follow-up period.
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LVEF TRAJECTORY IN HFPEF
In a retrospective community-based study in which repeat echocardiograms were executed at discretion of the care provider, mean LVEF fell by 5.8% over a 5-year period with a larger fall in the presence of coexisting CAD. 6 This fall in mean LVEF was substantially larger than the fall observed by Lupón et al, 1 which only amounted to 2% over the initial 5-year period. Unequal prevalence of CAD (23 versus 14%) most likely accounted for the discrepant outcome. This study also looked at the LVEF trajectory in HFrEF patients and observed a steady 6.9% increase over a 5-year period. 6 A similar study in HFrEF by Lupón et al 2 expanded the follow-up period to 15 years and observed an inverted U shaped relation whereby LVEF indeed increased over the initial 10 years but slowly declined afterward. This difference in reported LVEF trajectories in HFrEF illustrates the importance of duration of follow-up. Two additional studies looked at the longitudinal evolution of the HFpEF phenotype but expressed their findings not as change of LVEF over time but as percent of patients transitioning from HFpEF to HFrEF. A Japanese study characterizing the HFmrEF phenotype showed 8% and 4% of HFpEF patients to develop, respectively, HFmrEF and HFrEF over a 3-year period. 7 In this study, the prevalence of CAD was exceptionally high at 44%. It is, therefore, no surprise that transition to HFmrEF and HFrEF was much higher than in the study by Lupón et al, 1 who over an 11-year time period observed only 9.5% and 1.6% of HFpEF patients to, respectively, transition to HFmrEF and HFrEF. Finally, a retrospective analysis of a community-based HF population yielded an outlying result as it showed an HFrEF transition to occur in 33% of HFpEF patients over a 5-year period. 8 In this study, 32.5% of HFpEF patients had suffered a previous myocardial infarction, and most importantly, HFpEF was defined by an LVEF >40%. The latter hinders interpretation of the findings because HFmrEF patients were included as HFpEF patients, whereas HFmrEF resembles HFrEF with a high prevalence of CAD and a high incidence of new ischemic events. 9 Collectively, most of the previous and the present study concur that in HFpEF without CAD LVEF shows little change over time and the vast majority of HFpEF patients, therefore, adhere to the HFpEF phenotype even after prolonged observation periods.
RIGHT VENTRICULAR EF VERSUS LVEF
The near constancy of LVEF over time contrasts sharply with the rapid decline in right ventricular (RV) function in HFpEF. 10 Over a 4-year time period, there was already a 10% decline in RV fractional area change and a 21% increase in RV diastolic area, both of which exceeded by far corresponding changes in LV systolic function. The rapid deterioration in RV systolic function and the near constancy of LV systolic function imply presence of myocardial overload in the RV because of pulmonary hypertension but absence of a similar overload mechanism in the LV, where remodeling is predominantly driven by microvascular inflammation and endothelial dysfunction.
CAD HFPEF PHENOTYPE
The present study by Lupón et al 1 reinforces the ominous implications of coexisting CAD in HFpEF. A previous retrospective analysis of the effects of CAD in HFpEF revealed presence of CAD to result in a minimal difference in baseline LVEF (61 versus 62 %) but a 4-fold faster decline in LVEF over a 3.6 year period (−4.6% versus −1.0%). 11 The prospective study by Lupón et al 1 confirms these findings: HFpEF patients with CAD had slightly lower baseline LVEF and a faster decline in LVEF (−7% over a 3.6-year period). Despite a high frequency of revascularization procedures (16/18 pts), all HFpEF patients with CAD died within 5 years. These findings raise serious concerns about possible cardiomyocyte injury because of additive effects of macrovascular CAD related ischemia and microvascular HFpEF related ischemia. 12 Presence of cardiomyocyte injury was recently also suggested by a study reporting elevated troponin T plasma levels in HFpEF.
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LVEF(50-55) HFPEF PHENOTYPE
Another intriguing observation made by Lupón et al 1 pertains to the HFpEF patients with an LVEF ranging from 50% to 55%. The vast majority (67%) of the HFpEF patients who transitioned from HFpEF to HFmrEF had a baseline LVEF within the 50% to 55% range. A comparable observation was previously made in Japan. 14 In this study, 11% of HFpEF patients transitioned to HFmrEF after 2.5 years. Receiver-operating characteristic curve analysis revealed a baseline LVEF range from 50% to 55% to predict transition to HFmrEF with an area under the curve of 0.98. Both studies suggest that within the 50% to 55% range there is substantial overlap between HFmrEF and HFpEF which is of clinical relevance because HFmrEF responds favorably to neurohumoral inhibition. A positive response to candesartan in HF patients with an LVEF ranging from 50% to 55% was indeed observed in a retrospective analysis of the CHARM program (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) which treated LVEF as a continuous variable. 15 In this analysis, candesartan improved the primary outcome of cardiovascular death or HF hospitalization and the secondary outcome of HF hospitalization well into the 50% to 55% LVEF range.
CONCLUSIONS
Over an 11-year period, Lupón et al 1 observed in a prospectively recruited cohort of HFpEF patients a ±0.5% annual decline in LVEF and adherence to the HFpEF phenotype in 88.9% of patients. This phenotypic persistence of HFpEF establishes HFpEF and HFrEF as distinct HF phenotypes. The occasional fall in LVEF in an HFpEF patient suggests presence of concomitant CAD or misclassified HFmrEF especially with an LVEF in the range from 50% to 55%.
